Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Background Blood pressure reduction achieved with beta-blockers and diuretics is the best recorded intervention to date for prevention of cardiovascular morbidity and death in patients with hypertension. Left ventricular hypertrophy (LVH) is a strong independent indicator of risk of cardiovascular morbidity and death. We aimed to establish whether selective blocking of angiotensin II improves LVH beyond reducing blood pressure and, consequently, reduces cardiovascular morbidity and death. Methods We did a double-masked, randomised, parallel-group trial in 9193 participants aged 55-80 years with essential hypertension (sitting blood pressure 160-200/95-115 mm Hg) and LVH ascertained by electrocardiography (ECG). We assigned participants once daily losartan-based or atenolol-based antihypertensive treatment for at least 4 years and until 1040 patients had a primary cardiovascular event (death, myocardial infarction, or stroke). We used Cox regression analysis to compare regimens. Findings Blood pressure fell by 30.2/16.6 (SD 18.5/10.1) and 29.1/16.8 mm Hg (19.2/10.1) in the losartan and atenolol groups, respectively. The primary composite endpoint occurred in 508 losartan (23.8 per 1000 patient-years) and 588 atenolol patients (27.9 per 1000 patient-years; relative risk 0.87, 95% CI 0.77-0.98, p=0.021). 204 losartan and 234 atenolol patients died from cardiovascular disease (0.89, 0.73-1.07, p=0.206); 232 and 309, respectively, had fatal or non-fatal stroke (0.75, 0.63-0.89, p=…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“an 11% reduction in myocardial infarction (MI)”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [186]
In the citing paper
“This study showed that each 10 mm Hg decrease in systolic BP (achieved with either an ACE inhibitor [captopril] or a beta blocker [atenolol]) was associated with a 15% reduction in DM-related mortality”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [186]
In the citing paper
“and a 13% reduction in the microvascular complications of retinopathy or DKD.186”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [186]
In the citing paper
“Clinical trial data show that intensifying therapy with BP-lowering medications slows the progression of DKD and retinopathy, though vigilance in monitoring renal function during intensive BP therapy is recommended.185,186,201–203”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [186]
In the citing paper
“Optimization of glucose and BP are the proven strategies for primary prevention of diabetic retinopathy and for slowing the progression of preexisting nonproliferative retinopathy.78,185,186,193,522,523”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [186]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Hansson, L., Lindholm, L. H., Niskanen, L., Lanke, J., Hedner, T., Niklason, A., Luomanmäki, K., Dahlöf, B., de Faire, U., Mörlin, C., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(98)05012-0 · Cited by 2,014
Self-citationMorbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension)
Dahlöf, B., Hansson, L., Lindholm, L. H., Scherstén, B., Ekbom, T., & Wester, P.-O. (1991) · The Lancet · doi:10.1016/0140-6736(91)92589-t · Cited by 1,881
Self-citationAn updated coronary risk profile. A statement for health professionals.
Anderson, K. M., Wilson, P. W., Odell, P. M., & Kannel, W. B. (1991) · Circulation · doi:10.1161/01.cir.83.1.356 · Cited by 1,834
The Norwegian Multicenter Study Group (1981) · New England Journal of Medicine · doi:10.1056/nejm198104023041401 · Cited by 1,675
Hansson, L., Lindholm, L. H., Ekbom, T., Dahlöf, B., Lanke, J., Scherstén, B., Wester, P.-O., Hedner, T., & de Faire, U. (1999) · The Lancet · doi:10.1016/s0140-6736(99)10327-1 · Cited by 1,447
Self-citationReversal of Left Ventricular Hypertrophy in Hypertensive Patients
Dahlöf, B., Pennert, K., & Hansson, L. (1992) · American Journal of Hypertension · doi:10.1093/ajh/5.2.95 · Cited by 925
Self-citationLemon, D. (1987) · The Journal of Emergency Medicine · doi:10.1016/0736-4679(87)90192-2 · Cited by 563
Research works printed but not linked: 2
- Dhlöf, 1997, The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension Study: rationale, design, and methods, Am J Hypertens, 10, 705
- Mulrow, 2001, Pharmacotherapy for hypertension in the elderly (Cochrane review)
Cited by
Items 501–600 of 1,018
Diabetes Mellitus, the Renin-Angiotensin-Aldosterone System, and the Heart
Lim, H. S., MacFadyen, R. J., & Lip, G. Y. H. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.16.1737 · Cited by 138
Cipollone, F., Fazia, M., Iezzi, A., Pini, B., Cuccurullo, C., Zucchelli, M., de Cesare, D., Ucchino, S., Spigonardo, F., De Luca, M., et al. (2004) · Circulation · doi:10.1161/01.cir.0000121735.52471.ac · Cited by 138
Epidemiology, Pathophysiology, Prognosis, and Treatment of Systolic and Diastolic Heart Failure
Aronow, W. S. (2006) · Cardiology in Review · doi:10.1097/01.crd.0000175289.87583.e5 · Cited by 138
Ibsen, H., Wachtell, K., Olsen, M. H., Borch-Johnsen, K., Lindholm, L. H., Mogensen, C. E., Dahl??f, B., Devereux, R. B., de Faire, U., Fyhrquist, F., et al. (2004) · Journal of Hypertension · doi:10.1097/00004872-200409000-00026 · Cited by 137
Self-citationWilcox, R., Kupfer, S., & Erdmann, E. (2008) · American Heart Journal · doi:10.1016/j.ahj.2007.11.029 · Cited by 137
Bangalore, S., Kumar, S., Wetterslev, J., & Messerli, F. H. (2011) · BMJ · doi:10.1136/bmj.d2234 · Cited by 137
Evaluación y tratamiento de la hipertensión arterial en España. Documento de consenso
de la Sierra, A., Gorostidi, M., Marín, R., Redón, J., Banegas, J. R., Armario, P., Puig, J. G., Zarco, J., Llisterri, J. L., Sanchís, C., et al. (2008) · Medicina Clínica · doi:10.1157/13124015 · Cited by 148
Anti-inflammatory effects of angiotensin-(1-7) in ischemic stroke
Regenhardt, R. W., Desland, F., Mecca, A. P., Pioquinto, D. J., Afzal, A., Mocco, J., & Sumners, C. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.03.025 · Cited by 137
MacDonald, T. M., Williams, B., Webb, D. J., Morant, S., Caulfield, M., Cruickshank, J. K., Ford, I., Sever, P., Mackenzie, I. S., Padmanabhan, S., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.006986 · Cited by 137
Migraine and the Risk for Stroke and Cardiovascular Disease
Sacco, S., & Kurth, T. (2014) · Current Cardiology Reports · doi:10.1007/s11886-014-0524-1 · Cited by 137
Alfakih, K., Walters, K., Jones, T. R., Ridgway, J. P., Hall, A. S., & Sivananthan, M. U. (2004) · Hypertension · doi:10.1161/01.hyp.0000135249.66192.30 · Cited by 137
Palatini, P., Bénétos, A., & Julius, S. (2006) · Drugs · doi:10.2165/00003495-200666020-00001 · Cited by 136
Self-citationIs There a Rationale for Angiotensin Blockade in the Management of Obesity Hypertension?
Sharma, A. M. (2004) · Hypertension · doi:10.1161/01.hyp.0000132568.71409.a2 · Cited by 136
The Combination of Beta-Blockers and ACE Inhibitors Across the Spectrum of Cardiovascular Diseases
Strauss, M. H., Hall, A. S., & Narkiewicz, K. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07248-1 · Cited by 136
Guía europea de prevención cardiovascular en la práctica clínica: Adaptación española del CEIPC 2008
Lobos, J. M., Royo‐Bordonada, M. Á., Brotons, C., Álvarez-Sala, L., Armario, P., Maiques, A., Mauricio, D., Sans, S., Villar, F., Lizcano‐Álvarez, A., et al. (2008) · Revista Española de Salud Pública · doi:10.1590/s1135-57272008000600002 · Cited by 142
Lackland, D. T., Elkind, M. S. V., D'Agostino, R., Dhamoon, M. S., Goff, D. C., Higashida, R. T., McClure, L. A., Mitchell, P. H., Sacco, R. L., Sila, C. A., et al. (2012) · Stroke · doi:10.1161/str.0b013e31825bcdac · Cited by 135
Zanchetti, A., & Ruilope, L. M. (2002) · Journal of Hypertension · doi:10.1097/00004872-200211000-00001 · Cited by 135
Effects of ACE-Inhibitors and Angiotensin Receptor Blockers on Inflammation
Raimondo, D. D., Tuttolomondo, A., Buttà, C., Miceli, S., Licata, G., & Pinto, A. V. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212802481282 · Cited by 135
Cardiac remodelling and RAS inhibition
Ferrario, C. M. (2016) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944716642677 · Cited by 135
DiNicolantonio, J. J., Fares, H., Niazi, A. K., Chatterjee, S., D’Ascenzo, F., Cerrato, E., Biondi‐Zoccai, G., Lavie, C. J., Bell, D. S. H., & O’Keefe, J. H. (2015) · Open Heart · doi:10.1136/openhrt-2014-000230 · Cited by 134
Derington, C. G., King, J. B., Herrick, J. S., Shimbo, D., Kronish, I. M., Saseen, J. J., Muntner, P., Moran, A. E., & Bress, A. P. (2020) · Hypertension · doi:10.1161/hypertensionaha.119.14360 · Cited by 134
Kane, G. C., Xu, N., Mistrik, E., Roubicek, T., Stanson, A. W., & Garovic, V. D. (2010) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfp393 · Cited by 134
Law, J. P., Pickup, L. C., Pavlović, D., Townend, J., & Ferro, C. J. (2022) · Journal of Human Hypertension · doi:10.1038/s41371-022-00751-4 · Cited by 136
Should we restrict chloride rather than sodium?
McCarty, M. F. (2004) · Medical Hypotheses · doi:10.1016/j.mehy.2003.11.005 · Cited by 134
Tissue renin angiotensin systems
Ré, R. N. (2004) · Medical Clinics of North America · doi:10.1016/s0025-7125(03)00124-x · Cited by 132
Li, Y., Gonzalez, P., & Zhang, L. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.05.010 · Cited by 132
Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy
Julius, S., Alderman, M. H., Beevers, G., Dahlöf, B., Devereux, R. B., Douglas, J. G., Edelman, J. M., Harris, K. E., Kjeldsen, S. E., Nesbitt, S. D., et al. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.11.029 · Cited by 132
Self-citationNovel therapeutic targets for hypertension
Paulis, L., & Unger, T. (2010) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.85 · Cited by 132
Semlitsch, T., Jeitler, K., Hemkens, L. G., Horvath, K., Nagele, E., Schuermann, C., Pignitter, N., Herrmann, K., Waffenschmidt, S., & Siebenhofer, A. (2013) · Sports Medicine · doi:10.1007/s40279-013-0065-6 · Cited by 133
Mourad, J., Waeber, B., Zannad, F. E., Laville, M., Duru, G., & jak, M. A. (2004) · Journal of Hypertension · doi:10.1097/00004872-200412000-00021 · Cited by 132
Antioxidant therapy for management of oxidative stress induced hypertension
Ahmad, K. A., Yuan, D. Y., Nawaz, W., Hong, Z., Zhuo, C. X., Talal, B., Taleb, A., Mais, E., & Qi-long, D. (2017) · Free Radical Research · doi:10.1080/10715762.2017.1322205 · Cited by 132
Development of heart failure in recent hypertension trials
Tocci, G., Sciarretta, S., & Volpe, M. (2008) · Journal of Hypertension · doi:10.1097/hjh.0b013e3282fe1d3d · Cited by 131
Dandona, P., Aljada, A., Chaudhuri, A., & Bandyopadhyay, A. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030178 · Cited by 131
Cerebroprotection mediated by angiotensin II
Fournier, A. E., Messerli, F. H., Achard, J. M., & Fernandez, L. A. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.10.060 · Cited by 131
Sarafidis, P. A., & Bakris, G. L. (2008) · Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2008.07309.x · Cited by 130
Okin, P. M., Devereux, R. B., Harris, K. E., Jern, S., Kjeldsen, S. E., Julius, S., Edelman, J. M., Dahlöf, B., & for the LIFE Study Investigators (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-5-200709040-00006 · Cited by 130
Self-citationBurnier, M., & Zanchi, A. (2005) · Journal of Hypertension · doi:10.1097/01.hjh.0000191244.91314.9d · Cited by 129
Evidence-based Practice Guideline for the Treatment of CKD
(2009) · Clinical and Experimental Nephrology · doi:10.1007/s10157-009-0237-8 · Cited by 129
Izzo, J. L., & Gradman, A. H. (2004) · Medical Clinics of North America · doi:10.1016/j.mcna.2004.06.002 · Cited by 128
Ohashi, K., Ouchi, N., & Matsuzawa, Y. (2011) · American Journal of Hypertension · doi:10.1038/ajh.2010.216 · Cited by 127
Bhandari, S., Ives, N., Brettell, E. A., Valente, M., Cockwell, P., Topham, P. S., Cleland, J. G., Khwaja, A., & El Nahas, M. (2016) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv346 · Cited by 127
Offen, W., Chuang‐Stein, C., Dmitrienko, A. A., Littman, G. S., Maca, J., Meyerson, L., Muirhead, R. J., Stryszak, P., Baddy, A., Chen, K., et al. (2007) · Drug Information Journal · doi:10.1177/009286150704100105 · Cited by 127
de Cavanagh, E. M. V., Ferder, M., Inserra, F., & Ferder, L. (2009) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01176.2008 · Cited by 129
Hipertensão arterial no idoso: peculiaridades na fisiopatologia, no diagnóstico e no tratamento
Miranda, R. D., Perrotti, T. C., Bellinazzi, V. R., Nóbrega, T. M., Cendoroglo, M. S., & Neto, J. T. (2002) · Revista Brasileira de Hipertensão · Cited by 138
Migraine and vascular diseases: A review of the evidence and potential implications for management
Sacco, S., Ricci, S., & Carolei, A. (2012) · Cephalalgia · doi:10.1177/0333102412451361 · Cited by 127
Combination therapy in hypertension: An update
Kalra, S., Kalra, B., & Agrawal, N. K. (2010) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-2-44 · Cited by 127
Clinical Outcomes in the Diabetes Cohort of the International Verapamil SR-Trandolapril Study
Bakris, G. L., Gaxiola, E., Messerli, F. H., Mancia, G., Erdine, S., Cooper-DeHoff, R., & Pepine, C. J. (2004) · Hypertension · doi:10.1161/01.hyp.0000143851.23721.26 · Cited by 126
Ochodnicky, P., Henning, R. H., van Dokkum, R. P. E., & de Zeeuw, D. (2006) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-200606001-00009 · Cited by 126
Leiter, L. A., & Lewanczuk, R. Z. (2005) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2004.07.001 · Cited by 126
Sica, D. A., White, W. B., Weber, M. A., Bakris, G. L., Pérez, A., Cao, C., Handley, A., & Kupfer, S. (2011) · Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2011.00482.x · Cited by 126
Left ventricular mass change during treatment and outcome in patients with essential hypertension
Koren, M. J., Ulin, R. J., Koren, A., Laragh, J. H., & Devereux, R. B. (2002) · American Journal of Hypertension · doi:10.1016/s0895-7061(02)03061-3 · Cited by 126
Self-citationA reappraisal of loop diuretic choice in heart failure patients
Buggey, J., Mentz, R. J., Pitt, B., Eisenstein, E. L., Anstrom, K. J., Velazquez, E. J., & O’Connor, C. M. (2015) · American Heart Journal · doi:10.1016/j.ahj.2014.12.009 · Cited by 126
Nuclear-delimited Angiotensin Receptor-mediated Signaling Regulates Cardiomyocyte Gene Expression
Tadevosyan, A., Maguy, A., Villeneuve, L. R., Babin, J., Bonnefoy, A., Allen, B. G., & Nattel, S. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.121749 · Cited by 126
Exceptional early blood pressure control rates: The ACCOMPLISH trial
Jamerson, K., Bakris, G. L., Dahlöf, B., Pitt, B., Velazquez, E., Gupte, J., Lefkowitz, M., Hester, A., Shi, V., Kjeldsen, S. E., et al. (2007) · Blood Pressure · doi:10.1080/08037050701395571 · Cited by 125
Self-citationMedical reversal: why we must raise the bar before adopting new technologies.
Prasad, V. K., & Cifu, A. S. (2011) · PubMed Central · Cited by 125
Main, C., Palmer, S., Griffin, S., Jones, L., Orton, V, Sculpher, M., Henderson, R., Sudlow, C., Hawkins, N., & Riemsma, R. (2004) · Health Technology Assessment · doi:10.3310/hta8400 · Cited by 125
Mj, B. (2008) · Circulation · doi:10.1161/circulationaha.108.787630 · Cited by 125
Role of vitamins and minerals in prevention and management of type 2 diabetes mellitus
Martini, L. A., Catania, A. S., & Ferreira, S. R. G. (2010) · Nutrition Reviews · doi:10.1111/j.1753-4887.2010.00296.x · Cited by 125
Initial Treatment of Hypertension
August, P. (2003) · New England Journal of Medicine · doi:10.1056/nejmcp010357 · Cited by 126
de Diagnóstico, G. D. T., & de Cardiología, T. D. L. I. C. C. D. L. S. E. (2005) · Revista Española de Cardiología · doi:10.1157/13078554 · Cited by 125
McGraw, A. P., Bagley, J., Chen, W., Galayda, C., Nickerson, H., Armani, A., Caprio, M., Carmeliet, P., & Jaffe, I. Z. (2013) · Journal of the American Heart Association · doi:10.1161/jaha.112.000018 · Cited by 125
Hypertension, Angiotensin, and Stroke: Beyond Blood Pressure
Iadecola, C., & Gorelick, P. B. (2004) · Stroke · doi:10.1161/01.str.0000115162.16321.aa · Cited by 124
Shen, L., Shah, B. R., Reyes, E., Thomas, L. E., WOJDYLA, D. M., Diem, P., Leiter, L. A., Charbonnel, B. H., VIu, M., Horton, E. S., et al. (2013) · BMJ · doi:10.1136/bmj.f6745 · Cited by 124
Pathophysiological regulation of the AT1-receptor and implications for vascular disease
Waßmann, S., & Nickenig, G. (2006) · Journal of Hypertension · doi:10.1097/01.hjh.0000220402.53869.72 · Cited by 124
Dhalla, I. A., Gomes, T., Yao, Z., Nagge, J. J., Persaud, N., Hellings, C., Mamdani, M., & Juurlink, D. N. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-6-201303190-00004 · Cited by 124
Ho, Y., Lin, C., Lin, Y., & Lo, M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018699 · Cited by 124
Toll-like receptors and diabetes: a therapeutic perspective
Dasu, M. R., Ramirez, S., & Isseroff, R. R. (2012) · Clinical Science · doi:10.1042/cs20110357 · Cited by 123
Lessons Learned From Recent Cardiovascular Clinical Trials: Part II
DeMets, D. L., & Califf, R. M. (2002) · Circulation · doi:10.1161/01.cir.0000023220.26465.89 · Cited by 123
Antiatherosclerotic and Anti-Insulin Resistance Effects of Adiponectin: Basic and Clinical Studies
Han, S. H., Sakuma, I., Shin, E. K., & Koh, K. K. (2009) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2009.06.004 · Cited by 123
Angiotensin II AT2 receptor subtype: an uprising frontier in cardiovascular disease?
Volpe, M., Musumeci, B., Paolis, P. D., Savoia, C., & Morganti, A. (2003) · Journal of Hypertension · doi:10.1097/00004872-200308000-00001 · Cited by 123
Chronic Management of Blood Pressure After Stroke
Pedelty, L., & Gorelick, P. B. (2004) · Hypertension · doi:10.1161/01.hyp.0000129170.50448.5f · Cited by 122
Okin, P. M., Devereux, R. B., Nieminen, M. S., Jern, S., Oikarinen, L., Viitasalo, M. T., Toivonen, L. K., Kjeldsen, S. E., & Dahlöf, B. (2005) · Circulation · doi:10.1161/circulationaha.105.569491 · Cited by 122
Self-citationDiamond, G. A., & Kaul, S. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.01.035 · Cited by 122
Renin angiotensin aldosterone inhibition in the treatment of cardiovascular disease
Ferrario, C. M., & Mullick, A. E. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.05.020 · Cited by 122
Hypertension management 2011: optimal combination therapy
Sever, P., & Messerli, F. H. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr177 · Cited by 123
Predictors of uncontrolled hypertension and antihypertensive medication nonadherence
Macedo, A. F., Morgado, M., Castelo-Branco, M., Rolo, S., & Pereira, L. (2010) · Journal of Cardiovascular Disease Research · doi:10.4103/0975-3583.74263 · Cited by 121
Cuspidi, C., Muiesan, M. L., Valagussa, L., Salvetti, M., Di Biagio, C., Agabiti-Rosei, E., Magnani, B., & Zanchetti, A. (2002) · Journal of Hypertension · doi:10.1097/00004872-200211000-00030 · Cited by 121
Montecucco, F., Pende, A., & Mach, F. (2009) · Mediators of Inflammation · doi:10.1155/2009/752406 · Cited by 121
Pimenta, E. (2011) · Hypertension Research · doi:10.1038/hr.2011.190 · Cited by 121
Zhang, J.-D., Patel, M. B., Song, Y.-S., Griffiths, R., Burchette, J. L., Ruiz, P., Sparks, M. A., Yan, M., Howell, D. N., Gómez, J. A., et al. (2012) · Circulation Research · doi:10.1161/circresaha.111.261768 · Cited by 121
Bates, B., Choi, J. Y., Duncan, P. W., Glasberg, J. J., Graham, G. D., Katz, R. C., Lamberty, K., Reker, D., & Zorowitz, R. (2005) · Stroke · doi:10.1161/01.str.0000180432.73724.ad · Cited by 120
Overcoming barriers to effective blood pressure control in patients with hypertension
Düsing, R. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x120995 · Cited by 120
Microcirculation and Macrocirculation in Hypertension: A Dangerous Cross-Link?
Laurent, S., Rosei, C. A., Bruno, R. M., & Rizzoni, D. (2022) · Hypertension · doi:10.1161/hypertensionaha.121.17962 · Cited by 120
Recommendations for special populations: diabetes mellitus and the metabolic syndrome
Sowers, J. R. (2003) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2003.07.009 · Cited by 120
Rakugi, H., Enya, K., Sugiura, K., & Ikeda, Y. (2012) · Hypertension Research · doi:10.1038/hr.2012.8 · Cited by 120
Coronary artery disease in Africa and the Middle East
Almahmeed, W. A., Arnaout, M. S., Chettaoui, Ibrahim, Kurdi, Taher, T., & Mancia (2012) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s26414 · Cited by 119
Unger, T., Paulis, L., & Sica, D. A. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr253 · Cited by 119
Frishman, W. H., & Saunders, E. (2011) · Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2011.00515.x · Cited by 119
Dahlöf, B., Gosse, P., Guéret, P., Dubourg, O., SIMONE, G. D., Schmieder, R. E., IuA, K., Puig, J. G., Matos, L., de Leeuw, P. W., et al. (2005) · Journal of Hypertension · doi:10.1097/01.hjh.0000187253.35245.dc · Cited by 119
Self-citationLeft Ventricular Hypertrophy: The Next Treatable, Silent Killer?
Gardin, J. M., & Lauer, M. S. (2004) · JAMA · doi:10.1001/jama.292.19.2396 · Cited by 118
Yang, X., So, W.-Y., Kong, A. P. S., Ho, C.-S., Lam, C. W. K., Stevens, R. J., Lyu, R. R., Yin, D. D., Cockram, C. S., Tong, P. C. Y., et al. (2007) · Diabetes Care · doi:10.2337/dc06-1273 · Cited by 118
The past, present and future of renin–angiotensin aldosterone system inhibition
Mentz, R. J., Bakris, G. L., Waeber, B., McMurray, J. J. V., Gheorghiade, M., Ruilope, L. M., Maggioni, A. P., Swedberg, K., Piña, I. L., Fiuzat, M., et al. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.10.007 · Cited by 118
Role of angiotensin II AT1 receptor activation in cardiovascular diseases
Billet, S., Aguilar, F., Baudry, C., & Clauser, É. (2008) · Kidney International · doi:10.1038/ki.2008.358 · Cited by 118
(2022) · PubMed Central · doi:10.6515/acs.202205_38(3).20220321a · Cited by 117
Bang, C. N., Gerdts, E., Aurigemma, G. P., Boman, K., SIMONE, G. D., Dahlöf, B., Køber, L., Wachtell, K., & Devereux, R. B. (2014) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.113.001275 · Cited by 117
Self-citationLiu, R., Wei, L., & Zhang, P. (2021) · Nature Machine Intelligence · doi:10.1038/s42256-020-00276-w · Cited by 117
Blood Pressure Lowering for Primary and Secondary Prevention of Stroke
Zhang, H., Thijs, L., & Staessen, J. A. (2006) · Hypertension · doi:10.1161/01.hyp.0000231939.40959.60 · Cited by 117
Ibsen, H., Olsen, M. H., Wachtell, K., Borch‐Johnsen, K., Lindholm, L. H., Mogensen, C. E., Dahlöf, B., Snapinn, S. M., Wan, Y., & Lyle, P. A. (2006) · Diabetes Care · doi:10.2337/diacare.29.03.06.dc05-1724 · Cited by 117
Self-citationInsulin resistance in idiopathic dilated cardiomyopathy
Witteles, R. M., Tang, W. H. W., Jamali, A. H., Chu, J. W., Reaven, G. M., & Fowler, M. B. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.03.037 · Cited by 117
Carr, A. A., Kowey, P. R., Devereux, R. B., Brenner, B. M., Dahlöf, B., Ibsen, H., Lindholm, L. H., Lyle, P. A., Snapinn, S. M., Zhang, Z., et al. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.07.061 · Cited by 117
Self-citation
Metadata
- Authors
- Dahlöf, B., Devereux, R. B., Kjeldsen, S. E., Julius, S., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., Kristiansson, K., Lederballe-Pedersen, O., Lindholm, L. H., Nieminen, M. S., Omvik, P., Oparil, S., & Wedel, H.
- Affiliations
- Sahlgrenska University Hospital (SE)
- Oslo University Hospital (NO)
- University of Michigan (US)
- Birmingham City Hospital (GB)
- Helsinki University Hospital (FI)
- Glostrup Hospital (DK)
- Umeå University (SE)
- Haukeland University Hospital (NO)
- University of Alabama at Birmingham (US)
- Nordic School of Public Health (SE)
- Corresponding author
- Dahlöf, Björn
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2002-03
- Volume
- 359
- Issue
- 9311
- Pages
- 995-1003
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2133217116
- Cited by
- 5,407
- References
- 29
- Citations by year
- 2026: 37 · 2025: 51 · 2024: 51 · 2023: 69 · 2022: 63 · 2021: 75 · 2020: 74 · 2019: 82 · 2018: 106 · 2017: 144 · 2016: 131 · 2015: 152 · 2014: 208 · 2013: 200 · 2012: 265
- FWCI
- 333.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- UEA Digital Repository (University of East Anglia) (submittedVersion)
- STM:n Hallinnonalan avoin julkaisuarkisto (Julkari) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Nursing › Nutrition and Dietetics › Sodium Intake and Health
- Keywords
- atenolol, essential hypertension, left ventricular hypertrophy, angiotensin receptor blockers, beta-blockers, cardiovascular morbidity, cardiovascular mortality, stroke, myocardial infarction, blood pressure reduction, new-onset diabetes, antihypertensive therapy, elderly patients, secondary prevention of cardiovascular disease, renin-angiotensin system blockade
- MeSH terms
- Aged, Aged, 80 and over, Antihypertensive Agents, Atenolol, Cardiovascular Diseases, Double-Blind Method, Female, Humans, Hypertension, Male, Middle Aged, Losartan, Diabetes Complications, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.